Home › Chronic Granulomatous Disease › Maryland
Pag-aaral pangklinika para sa Chronic Granulomatous Disease sa Maryland
6 pag-aaral para sa Chronic Granulomatous Disease ang naghahanap ng mga kalahok sa mga site sa Maryland.
Opisyal na teksto ng pag-aaral (English)
Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists
- National Institutes of Health Clinical Center, Bethesda
Nagre-recruitPhase 1/2
Edad 4 hanggang 65 · Lahat ng kasarian · Na-update Okt 5, 2026 · NCT05463133NADPH Oxidase Correction in mRNA-transfected Granulocyte-enriched Cells in Chronic Granulomatous Disease (CGD)
- National Institutes of Health Clinical Center, Bethesda
Nagre-recruitPhase 1
Edad 18 hanggang 75 · Kalalakihan · Na-update Okt 2, 2026 · NCT05189925Evaluation of Patients With Immune Function Abnormalities
- National Institutes of Health Clinical Center, Bethesda
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Lahat ng edad · Lahat ng kasarian · Na-update Set 22, 2026 · NCT00128973Recruitment and Apheresis Collection of Peripheral Blood Hematopoietic Stem Cells, Mononuclear Cells and Granulocytes
- National Institutes of Health Clinical Center, Bethesda
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Edad 18 hanggang 70 · Lahat ng kasarian · Na-update Set 22, 2026 · NCT00001405Prevalence of Antibodies and Cytokines in Participants With Chronic Granulomatous Disease
- Home-based telemedicine, Annapolis
Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update Ago 17, 2026 · NCT06605378Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease
- National Institutes of Health Clinical Center, Bethesda
Nagre-recruitPhase 1/2
Edad 18 hanggang 75 · Kalalakihan · Na-update Ago 13, 2026 · NCT06325709Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.